Colorado is currently home to 1773 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study in Parkinson Disease of Exercise
Recruiting
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax or 2)80-85% HRmax 4 times per week. The primary objective is to test whether the progression of the signs of Parkinson's disease is attenuated at 12 mon... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
11/12/2024
Locations: University of Colorado, Denver, Aurora, Colorado
Conditions: Parkinson Disease
The Role of Laryngopharyngeal Reflux in IPF
Recruiting
The primary objective of this study is to show that the Supraglottic Index (SGI) is an easily-collected index that accurately identifies the presence and severity of laryngopharyngeal reflux (LPF) in idiopathic pulmonary fibrosis (IPF).
Gender:
ALL
Ages:
Between 40 years and 95 years
Trial Updated:
11/12/2024
Locations: National Jewish Health, Denver, Colorado
Conditions: IPF, Reflux
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
Recruiting
Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Gender:
ALL
Ages:
Between 1 month and 79 years
Trial Updated:
11/12/2024
Locations: Children's Hospital of Colorado, Aurora, Colorado
Conditions: Adenovirus, Primary Immune Deficiency Disorder
Cold and Heat Investigation to Lower Levels of Depression
Recruiting
This study will recruit 112 medically healthy adults (aged 18-65) currently experiencing depressive symptoms to be randomized to receive either a single Whole Body Hyperthermia (heat therapy) treatment or a Whole Body Hyperthermia treatment followed by a cold water plunge. Participants will complete a baseline assessment of their depressive symptoms as well as 1-week and 2-week post-treatment followup assessments.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/11/2024
Locations: Vail Health Behavioral Health Innovation Center, Edwards, Colorado
Conditions: Depression, Mood Disorders
Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL
Recruiting
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: Sarah Cannon Research Institute, Denver, Colorado
Conditions: Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
Recruiting
The objective of this study is to collect information on patients with cardiomyopathy (CM) due to mutations in the MYBPC3 gene, to evaluate their disease course, burden of illness, risk factors for this disease, and the quality of life (QoL). This study will also collect information on treatments, procedures and outcome in infants and children up to 18 yrs who have this mutation.
Gender:
ALL
Ages:
Between 0 years and 18 years
Trial Updated:
11/11/2024
Locations: University of Colorado Hospital - Anschutz Medical Campus, Aurora, Colorado
Conditions: Cardiomyopathy
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Recruiting
CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the study treatment) in adults with acute myeloid leukemia (AML) that has come back after prior treatment (relapsed) or did not respond or is no longer responding to other treatment (refractory). Participants must have received at least 1 but not more than 3 prior lines of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: Colorado Blood Cancer Institute, Denver, Colorado
Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Neurophysiologic Biomarkers in Rett Syndrome
Recruiting
The goal of this observational study is to identify candidate biomarkers in individuals with Rett Syndrome (RTT). The main questions it aims to answer are: * Do these biomarkers change during clinical changes in individuals with RTT? * Are biomarkers stable over time in clinically stable individuals? * Do these biomarkers correlate with severity of RTT? Participants will be asked to undergo an electroencephalogram (EEG) with measurements of Evoked Potentials (EP) to measure electrical activity... Read More
Gender:
FEMALE
Ages:
Between 1 year and 18 years
Trial Updated:
11/08/2024
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Rett Syndrome, RTT, Rett Syndrome, Atypical
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Recruiting
The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: University of Colorado Hospital - Anschutz Medical Campus, Aurora, Colorado
Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): the CORCINCH-HF Study
Recruiting
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: University of Colorado, Aurora, Colorado
Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
9-ING-41 in Pediatric Patients with Refractory Malignancies.
Recruiting
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.
Gender:
ALL
Ages:
22 years and below
Trial Updated:
11/07/2024
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma
Clinical and Basic Investigations Into Congenital Disorders of Glycosylation
Recruiting
The purpose of this research is to study the natural history of congenital disorders of glycosylation and its causes and treatments.
Gender:
ALL
Ages:
All
Trial Updated:
11/07/2024
Locations: Children's Hospital of Colorado, Aurora, Colorado
Conditions: Congenital Disorders of Glycosylation